The stock's fall snapped a seven-day winning streak.
The Cigna Group (NYSE:CI – Get Free Report) has been assigned a consensus rating of “Buy” from the seventeen research firms that are presently covering the firm, Ratings reports. Two research analysts ...
Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth. See why I rate CI stock a buy at current prices.
To continue reading and help Philly news thrive, unlock this exclusive offer for unlimited digital access to Inquirer.com and ...
The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the ...
Jefferson Health and Cigna have reached terms on a new network provider contract three weeks after their previous deal ...
The Cigna Group stands poised to reap the rewards of utilization normalization in the back-half of the decade. Specifically, the company is taking steps to reduce exposure to government programs such ...
In this article, we are going to take a look at where The Cigna Group (NYSE:CI) stands against other best healthcare stocks to invest in. Healthcare stocks experienced a challenging year in 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results